Dyne Therapeutics (DYN) Income from Continuing Operations (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Income from Continuing Operations of 262593000.0 for Q2 2026, down 140.54% year-over-year from 647663347.82 in Q2 2025, and down 49.82% quarter-over-quarter from 175270000.0 in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Income from Continuing Operations for 8 consecutive years, with 262593000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 140.54% year-over-year to 262593000.0; the TTM figure through Jun 2026 stood at 657201000.0 (down 53.32% YoY), while the FY2025 annual figure was 857568000.0, down 41.6% from the prior year.
- Income from Continuing Operations retreated to 262593000.0 in Q2 2026 per DYN's latest filing, from 175270000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 62515000.0 in Q1 2022 and bottomed at 262593000.0 in Q2 2026.
- Historically, Income from Continuing Operations has averaged 131205333.33 across 5 years, with a median of 108743000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 193.23% — and 2025, when it jumped 56.35%.
- Dyne Therapeutics' Income from Continuing Operations stood at 152425000.0 in 2022, then sank by 38.9% to 211712000.0 in 2023, then soared by 55.37% to 94497000.0 in 2024, then fell by 17.48% to 111018000.0 in 2025, then slumped by 136.53% to 262593000.0 in 2026.
- Business Quant data shows DYN's Income from Continuing Operations at 262593000.0 in Q2 2026, 175270000.0 in Q1 2026, and 111018000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Dyne Therapeutics | 4.01 Bn | 4.01 Bn | - | -173.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -173.87 Mn |
| Mar 31, 2026 | -125.89 Mn |
| Dec 31, 2025 | -108.47 Mn |
| Sep 30, 2025 | -108.32 Mn |
| Jun 30, 2025 | -109.26 Mn |
| Mar 31, 2025 | -122.14 Mn |
| Dec 31, 2024 | -89.52 Mn |
| Sep 30, 2024 | -96.29 Mn |
| Jun 30, 2024 | -72.07 Mn |
| Mar 31, 2024 | -69.29 Mn |
| Dec 31, 2023 | -65.94 Mn |
| Sep 30, 2023 | -60.08 Mn |
| Jun 30, 2023 | -66.59 Mn |
| Mar 31, 2023 | -45.10 Mn |
| Dec 31, 2022 | -38.80 Mn |
| Sep 30, 2022 | -41.38 Mn |
| Jun 30, 2022 | -52.98 Mn |
| Mar 31, 2022 | -36.44 Mn |
| Dec 31, 2021 | -51.78 Mn |
| Sep 30, 2021 | -42.58 Mn |